Vascular Changes Persist After Multisystem Inflammatory Syndrome in Children

2024-01-18

临床结果AHA会议

THURSDAY, Jan. 18, 2024 -- Multisystem inflammatory syndrome in children (MIS-C) may be associated with an increased risk for future cardiovascular complications due to significant persistent vascular alterations, according to a research letter published online Jan. 16 in JAMA Pediatrics.

Julie Boever, from Ludwig Maximilian University of Munich, and colleagues conducted a case-control study of 17 patients with MIS-C and 17 matched controls with a median follow-up of 114.5 days.

The researchers found that during the acute phase, patients with MIS-C showed significantly damaged microcirculation, including lower median microvascular flow index (2.36 versus 2.80), total vessel density (16.14 versus 19.61 mm/mm2), and proportion of perfused vessels (12.31 versus 18.10 percent) compared with controls. There was alteration of vessel diameter distribution with significant capillary rarefication. Even without ongoing inflammation, impaired microcirculatory parameters persisted during follow-up. These findings persisted when adjusting for age, body mass index, and sex. In MIS-C, the augmentation index was significantly increased only during follow-up (median, −7.05 versus −18.01).

"This study emphasizes the importance of understanding the vascular impact of MIS-C during the acute phase and follow-up period to provide appropriate medical care and interventions," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Posted January 2024

More news resources

FDA Medwatch Drug Alerts

Daily MedNews

News for Health Professionals

New Drug Approvals

New Drug Applications

Drug Shortages

Clinical Trial Results

Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.